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ABSTRACT
Bluetongue virus (BTV) causes bluetongue, a major hemorrhagic disease of ruminants. In order to investigate the molecular de-
terminants of BTV virulence, we used a BTV8 strain minimally passaged in tissue culture (termed BTV8L in this study) and a
derivative strain passaged extensively in tissue culture (BTV8H) in in vitro and in vivo studies. BTV8L was pathogenic in both
IFNAR/mice and in sheep, while BTV8H was attenuated in both species. To identify genetic changes which led to BTV8H at-
tenuation, we generated 34 reassortants between BTV8L and BTV8H.We found that partial attenuation of BTV8L in IFNAR
/
mice was achieved by simply replacing genomic segment 2 (Seg2, encoding VP2) or Seg10 (encoding NS3) with the BTV8H ho-
mologous segments. Fully attenuated viruses required at least two genome segments from BTV8H, including Seg2 with either
Seg1 (encoding VP1), Seg6 (encoding VP6 and NS4), or Seg10 (encoding NS3). Conversely, full reversion of virulence of BTV8H
required at least five genomic segments of BTV8L. We also demonstrated that BTV8H acquired an increased affinity for glycos-
aminoglycan receptors during passaging in cell culture due to mutations in its VP2 protein. Replication of BTV8H was relatively
poor in interferon (IFN)-competent primary ovine endothelial cells compared to replication of BTV8L, and this phenotype was
determined by several viral genomic segments, including Seg4 and Seg9. This study demonstrated that multiple viral proteins
contribute to BTV8 virulence. VP2 and NS3 are primary determinants of BTV pathogenesis, but VP1, VP5, VP4, VP6, and VP7
also contribute to virulence.
IMPORTANCE
Bluetongue is one of the major infectious diseases of ruminants, and it is listed as a notifiable disease by theWorld Organization
for Animal Health (OIE). The clinical outcome of BTV infection varies considerably and depends on environmental and host-
and virus-specific factors. Over the years, BTV serotypes/strains with various degrees of virulence (including nonpathogenic
strains) have been described in different geographical locations. However, no data are available to correlate the BTV genotype to
virulence. This study shows that BTV virulence is determined by different viral genomic segments. The data obtained will help to
characterize thoroughly the pathogenesis of bluetongue. The possibility to determine the pathogenicity of virus isolates on the
basis of their genome sequences will help in the design of control strategies that fit the risk posed by new emerging BTV strains.
Bluetongue is one of the major infectious diseases of ruminantsand is caused by bluetongue virus (BTV), an arbovirus trans-
mitted by Culicoides spp. (1–3). BTV is a member of the Orbivirus
genus within the Reoviridae. The double-stranded RNA (dsRNA)
genome of BTV is composed of 10 segments encoding seven struc-
tural (VP1 to VP7) and four nonstructural (NS1 to NS4) proteins
(4, 5). The BTV virion is an icosahedral particle assembled in a
triple layer of capsid shells (6, 7). The viral core contains linear
dsRNA genomic segments associated with replication complexes
formed by three minor proteins, VP1 (RNA-dependent RNA
polymerase), VP4 (capping enzyme including methyltransferase),
and VP6 (RNA-dependent ATPase and helicase) enclosed by lay-
ers of VP3 (subcore) and VP7 (core) (4, 6, 8, 9). The outer capsid
is formed by two structural proteins, VP2 and VP5, that are re-
sponsible for cell attachment and entry (10–12). NS1, the largest
of the nonstructural proteins, forms tubules in the cytoplasm of
BTV-infected cells and is a positive regulator of viral protein syn-
thesis (13–15). NS2 is a major component of viral inclusion bodies
(VIB) which are the sites of BTV morphogenesis and RNA repli-
cation (16–18). NS3, the only BTV glycoprotein, is involved in
virus exit from infected cells and is thought to play a role in coun-
teracting the innate immune response of the host cell (19–21). The
recently discovered NS4 is the smallest of the BTV proteins, and it
also confers a replication advantage in cells in an antiviral state (5).
At present, there are 26 different BTV serotypes circulating world-
wide. The serotype is determined predominantly by VP2, which is
the most variable of BTV proteins and a main target of neutraliz-
ing antibodies (22–25).
Bluetongue is remarkably variable in its clinical manifesta-
tions, which can range from asymptomatic infection to a lethal
hemorrhagic fever (2, 26–28). This variability is due to several
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factors related both to the infected host and the virus (2, 29–33).
Over the years, BTV has been used extensively as a model to study
the orbivirus replication cycle, structural biology, and interaction
with the host cell. However, we have little understanding of the
molecular determinants of BTV virulence.
The northern European strain of BTV8 was the cause of one of
the largest outbreaks in the history of bluetongue. The virus
emerged in 2006 in an area between the Netherlands, Belgium,
and northern Germany and then spread throughout the conti-
nent, causing high mortality in naive sheep flocks and, occasion-
ally, also clinical disease in cattle (34–36). Interestingly, no clinical
signs were detected in sentinel sheep when the virus reached
northern Italy and Sardinia in 2008. Experimental infections with
the northern European strain of BTV8 (BTV8NET2006) and the
Italian strain of BTV8 (BTV8IT2008) confirmed a marked reduc-
tion in the virulence of the latter virus (33). A comparison of the
consensus sequences of both viruses showed 24 nucleotide differ-
ences between the two strains, resulting in eight amino acid resi-
due substitutions in VP1, VP2, VP4, VP6, NS1, and NS2.
Genetic drift occurring during natural transmission cycles
plays a significant role in the diversification of BTV strains and
their pathogenicity. Similarly, in vitro passage of BTV was shown
to have an impact on virulence in vivo (37–39). In particular,
strains isolated from severe clinical cases and consequently
adapted to mammalian tissue culture have been reported to have
reduced virulence in experimentally infected animals (33, 38). In-
terestingly, a decrease in pathogenicity was shown to occur even in
minimally passaged strains and was attributed to a genetic bottle-
neck that occurs after a single passage in mammalian cells rather
than to mutations in the consensus sequence (33). Conversely, live
attenuated vaccines and tissue culture-adapted strains of BTV
with a history of multiple passages in vitro show increased accu-
mulation of nucleotide substitutions correlating with increasing
numbers of passages in mammalian cells (39). Genomic segments
1, 2, and 8 (Seg1, Seg2, and Seg8, respectively, encoding VP1, VP2,
and NS2) were shown to be consistently mutated in high-passage-
number strains of BTV2, BTV4, and BTV9 viruses and to be at-
tenuated in murine models of bluetongue (39).
Here, in order to determine the roles played by specific BTV
genomic segments in virus adaptation to tissue culture and atten-
uation in vivo, we compared genetic and phenotypic differences
between BTV8NET2006 minimally passaged in tissue culture, a de-
rivative of this strain extensively passaged in cell culture, and 34
reassortants between the two viruses.
MATERIALS AND METHODS
Cell lines. All cell cultures were grown at 37°C in 5% CO2 humidified
atmosphere. BSR cells (a variant of BHK-21 cells; kindly provided by
Karl-Claus Conzelmann) were propagated in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and
1% penicillin-streptomycin (P-S). Transfections in BSR cells were per-
formed in DMEM with reduced FBS and no antibiotics. CPT-Tert cells
(40) are sheep choroid plexus cells immortalized with simian virus 40
(SV40) T antigen and human telomerase reverse transcriptase. CPT-Tert
cells were propagated in Iscove’s modified Dulbecco’s medium (IMDM)
supplemented with 10% FBS and 1% P-S. The CHO cell line is derived
from adult Chinese hamster ovary, and pgsA-745 (ATCC number CRL-
2242) is a CHO-derived cell line deficient in xylotransferase that does not
produce glycosaminoglycans (GAGs). Both cell lines were propagated in
Ham’s F-12 medium supplemented with 10% FBS and 1% P-S.
Primary endothelial cell cultures. Primary ovine aortic endothelial
cells (OvEC) were isolated directly from aortas harvested from euthanized
animals as recently described (41). Cells were maintained at 37°C in 5%
CO2 and 3% O2 for a maximum of three passages.
Virus strains. BTV8NET2006 (Pirbright reference collection number
NET2006/04) was originally isolated from a naturally infected sheep dur-
ing the 2006 outbreak in northern Europe and has been previously de-
scribed (5, 33). In this study, we refer to this virus as BTV8L. The subscript
“L” is used to indicate that this virus has a low number of passages in
cultures. BTV8H (H, high passage number) was obtained by 65 serial
passages of the BTV8L strain in BSR cells, followed by plaque purification.
Reverse genetics. Plasmids used for the rescue of BTV8L (resulting in
rgBTV8L) were described previously (5, 42). Plasmids used for the rescue
of BTV8H by reverse genetics (resulting in rgBTV8H) were derived by
site-directed mutagenesis of nonsynonymous sites in BTV8L. Reassor-
tants between rgBTV8L and rgBTV8H are denoted with the name of virus
forming the backbone (either BTV8L or BTV8H) followed by the substi-
tuted segment marked with the “L” or “H” subscript to indicate the virus
of origin. For example, BTV8LS2H is a reassortant containing the
rgBTV8L backbone with Seg2 from rgBTV8H. Rescued versions of both
BTV8L and BTV8H (rgBTV8L and rgBTV8H, respectively) and reassor-
tants between both parental viruses were obtained using established pro-
cedures for BTV reverse genetics (5, 42, 43).
Virus titrations and replication curves. Titers of viral stocks were
determined by standard plaque assays in CPT-Tert cells as previously
described (25, 43). Virus replication in CPT-Tert cells and OvEC was
assessed by infecting cells at a multiplicity of infection (MOI) of 0.01 and
collecting supernatants at 2, 24, 48, and 72 h postinfection (p.i.). To com-
pare replication kinetics of selected viruses in CHO and pgsA-745 cells,
infections were performed at an MOI of 0.01, and supernatants were
collected only at 72 h p.i. Supernatants were centrifuged for 5 min at
500  g to remove cell debris and then titrated by endpoint dilution
assays. Titers were expressed as the log10 50% tissue culture infective
doses/ml (TCID50/ml). All virus titration experiments were performed at
least three times independently. Statistical calculations were carried out
using GraphPad Prism.
BTV genome sequencing. The full genome sequence of BTV8H was
obtained using the Illumina platform. BSR cells were infected, and total
RNA was extracted using TRIzol reagent (Invitrogen). Single-stranded
RNA was precipitated using lithium chloride, and double-stranded RNA
was harvested from the supernatant by precipitation with isopropanol in
the presence of sodium acetate. Double-stranded RNA was used as a tem-
plate for full-length amplification of cDNA (FLAC) by reverse transcrip-
tion-PCR (RT-PCR) using established methods (44). Samples were ana-
lyzed using an Illumina Genome Analyser. The libraries were constructed
from the PCR samples using a TruSeq DNA sample preparation kit (Illu-
mina) according to the manufacturer’s instructions. Briefly, the DNA
samples were fragmented, the fragment was end repaired, and the 3= ends
were adenylated. After adaptor ligation steps, the fragments were purified
by size selection on agarose gel, and the fragments containing adaptors on
the 3= and 5= ends were enriched by PCR. Sequencing was performed on a
GAIIX sequencer (Illumina) according to the manufacturer’s protocol.
Genomes were assembled using Maq software (45) with BTV8L used as a
reference sequence. The assemblies were manually curated using Tablet
for sequence visualization (46), and consensus sequences were generated
as Fasta files.
In vivo experiments. Animal experiments were carried out at the
Istituto Zooprofilattico Sperimentale dell’Abruzzo e del Molise G. Capo-
rale (Teramo, Italy) in accordance with locally and nationally approved
protocols regulating animal experimental use (protocol no. 11427/2012).
Experiments in sheep were conducted in an insect-proof isolation unit
with veterinary care. Prior to the experiments the animals were confirmed
to be seronegative for BTV using a blocking enzyme-linked immunosor-
bent assay (ELISA), as described previously (33). Groups (n 5 animals
per group) of Dorset Poll sheep were infected intradermally with a total of
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2 106 PFU (in 5 ml) of BTV8L and BTV8H by multiple inoculations in
the inner leg and in the prescapular areas. Control animals were inocu-
lated with 5 ml of mock-infected cell supernatant. Blood samples were
collected from all animals daily for the first 15 days and at 17, 19, 21, and
28 days p.i. and then examined for the presence of viremia by quantitative
RT-PCR (qRT-PCR). Sera were tested by virus neutralization assay for the
presence of BTV-specific antibodies in the samples collected at 28 days p.i.
All sheep were examined for the presence of clinical signs and fever, start-
ing 1 week prior to inoculation and continuing for 15 days p.i., with
further observations on days 17, 19, 21, and 28 p.i. Clinical signs were
scored using a clinical reaction index (CRI) as previously described (33).
Transgenic mice deficient in type I interferon (IFN) receptor (129sv
IFNAR/) were maintained at biosafety level 3. For each experiment,
groups of adult mice matched for sex and age (n  5 per group) were
infected intraperitoneally or subcutaneously with 300 PFU or 3,000 PFU
of virus or mock-infected cell culture medium as a control. Mice were
examined for clinical signs daily until the experiment was concluded at 14
days p.i.
Serumneutralization assays. The presence of neutralizing antibodies
was assessed by neutralization assays as previously described (33, 43).
qRT-PCR. Levels of viremia in infected sheep were assessed by qRT-
PCR as described before (33). Red blood cells were lysed with water for 10
min on ice and centrifuged at 4°C for 10 min at 13,000 g. Armored West
Nile RNA (Asurage, USA) was spiked into each sample as an internal
control for nucleic acid extraction. Total RNA was extracted using a High
Pure nucleic acid extraction kit (Roche, Nutley, NJ) according to the
manufacturer’s instructions. For all samples, 250 ng of total RNA was
amplified by one-step qRT-PCR using primers and probes for BTV Seg5.
Armored RNA and -actin were amplified as control reactions.
Levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
-actin, IFN-, Mx1, and RSAD2 expression in infected OvEC were mea-
sured by qRT-PCR. Briefly, cells were seeded in 24-well plates and infected
48 h afterwards with rgBTV8L, rgBTV8H, or selected reassortants (MOI of
1). The medium was replaced after 1 h, and the cells were incubated for a
further 17 h at 37°C. Next, supernatants were collected, and monolayers
were directly lysed in 0.5 ml of TRIzol (Life Technologies). Phase separa-
tion was performed according to the manufacturer’s instructions, where-
upon the aqueous phase was mixed with ethanol and purified using an
RNeasy minikit (Qiagen), including an RNase Free/DNase Set on-column
DNase treatment step. Residual contaminating genomic DNA was re-
moved using a Turbo DNA-Free kit (Ambion) according to the manufac-
turer’s conditions. Reverse transcription was performed using 100 ng of
RNA using random hexamers and SuperScript III (Life Technologies) for
1 h at 45°C. Quantitative PCR (qPCR) was performed using Brilliant III
Ultra-Fast QPCR mastermix reagents (Agilent) and in-house designed
primers/probes (sequences available upon request) targeting ovine
GAPDH, -actin, IFN-, Mx1, and RSAD2. Samples were run on an
Mx3005P PCR machine with rgBTV8L-infected cells set as a calibrator.
GAPDH was used as normalizing gene against which fold induction was
determined for IFN-, Mx1, RSAD2, and -actin.
IFNprotection assays.Measurement of IFN levels in cell supernatants
was based on methods described previously (5, 41). Briefly, OvEC were
seeded in 24-well plates and infected after 2 days at an MOI of 1 with
selected viruses. Medium was replaced after 1 h of incubation, and super-
natants were collected 18 h after infection and treated for 20 min with UV
light to inactivate infectious virus. CPT-Tert cells were seeded in 96-well
plates, and 24 h later 2-fold serial dilutions of UV-treated supernatants or
serial dilutions of a known concentration of universal interferon (UIFN)
were added to the cells. After 24 h of incubation, supernatants were re-
moved, and cells were infected with encephalomyocarditis virus (EMCV)
and incubated for further 48 h. Cells were then inspected for EMCV-
induced cytopathic effect. The levels of IFN in supernatants collected from
BTV-infected OvEC were calculated based on the number of wells pro-
tected from EMCV-induced cell death compared to those of the UIFN
control wells.
Cell protection by pretreatment with UIFN was performed using
CPT-Tert cells. Cells were seeded in 24-well plates and 24 h later treated
with 1,000 units of UIFN. After 18 h of incubation, UIFN was removed,
and cells were infected with selected viruses at an MOI of 0.01. In parallel,
untreated CPT-Tert cells were infected with the same set of viruses. Inoc-
ula were replaced by fresh tissue culture medium 1.5 h later. At 48 h p.i.
supernatants were collected, and viral titers were determined by endpoint
dilution assay and expressed as the log10 TCID50/ml.
RESULTS
Phenotype of tissue culture-adapted BTV8. BTV8L was serially
passaged 65 times in BSR cells and plaque purified. The resulting
virus, BTV8H, and the parental BTV8L were then titrated in sheep
CPT-Tert cells and in primary ovine endothelial cells (OvEC).
CPT-Tert cells are unable to initiate an IFN response following
virus infection (5, 40), while OvEC are IFN competent (41). Both
viruses replicated very efficiently in IFN-deficient CPT-Tert cells,
but BTV8H reached titers approximately 100-fold higher than its
parental virus (Fig. 1A). Both viruses produced lower yields in
OvEC than in CPT-Tert cells, and BTV8L replicated better than
BTV8H in these cells (Fig. 1B).
Next, we determined the pathogenicity of BTV8L and BTV8H
in IFNAR/ mice. BTV8L was highly virulent in this mouse
model, inducing 100% mortality within 7 days p.i., whereas
BTV8H was completely attenuated (Fig. 1C). Next, we assessed the
virulence of BTV8L and BTV8H in sheep, the natural host of BTV
infection, in order to characterize further the phenotype of these
viruses in vivo. Sheep infected with BTV8L showed fever and gen-
eral clinical signs, including depression and mild respiratory dis-
tress. Viremia was detected in all BTV8L-infected animals (n 5)
from approximately day 4 p.i. until the end of the experiment at
day 28 p.i. On the other hand, sheep infected with BTV8H did not
show any clinical signs of bluetongue or viremia (Fig. 1D and E).
As expected, both BTV8L- and BTV8H-infected sheep developed
neutralizing antibodies although the antibody titers were lower in
the BTV8H-infected animals (Fig. 1F).
Genotype andphenotype of rgBTV8L and rgBTV8H.The data
obtained so far indicate that BTV8H had accumulated mutations
that affected virus replication in IFN-competent cells and resulted
in attenuation in vivo both in IFNAR/ mice and in sheep. Full-
genome sequencing of BTV8H revealed 31 nucleotide mismatches
compared to the sequence of BTV8L, out of which 16 resulted in
amino acid residue substitutions (Fig. 2A). Nonsynonymous mu-
tations were present in each of the 10 genomic segments and af-
fected all characterized BTV proteins with the exception of NS4.
In order to identify BTV8 genomic segments affecting viru-
lence, we rescued both BTV8L and BTV8H by reverse genetics. We
reconstructed BTV8H by substituting the 16 nucleotide mutations
of BTV8H into the BTV8L vectors by site-directed mutagenesis.
Hence, we rescued rgBTV8L with the same nucleotide sequence as
the original virus (BTV8L) while rgBTV8H was identical to the
original high-passage-number virus at the amino acid level but did
not contain the silent mutations present in the genome of BTV8H.
We then inoculated IFNAR/ mice with rgBTV8L and rgBTV8H
in order to test whether the phenotypes of the rescued viruses were
identical to those of the parental BTV8L and BTV8H. Groups of
five mice were inoculated intraperitoneally with 300 PFU of each
virus and monitored over a 14-day period (Fig. 2B). All mice in-
fected with rgBTV8H survived the challenge while rgBTV8L caused
100% mortality. These data showed that both rescued viruses re-
tained the phenotypes of the original viruses.
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Pathogenicity of reassortants between rgBTV8L and
rgBTV8H. In order to define the genomic segments carrying at-
tenuating mutations, we rescued in total 34 reassortants. A set of
reassortants was based upon the BTV8L backbone with a single
genomic segment or a combination of segments from BTV8H.
Four monoreassortants showed reduced mortality in IFNAR/
mice (Fig. 3A). In particular, BTV8LS2H and BTV8LS10H
caused no mortality in mice at an inoculation dose of 300 PFU and
caused 40% mortality with 3,000 PFU. Full attenuation using
both inoculation doses was achieved with double reassortants
BTV8LS1/2H (which contains Seg1 and Seg2 of BTV8H),
BTV8LS2/6H, and BTV8LS2/10H. These data suggest that VP2
and NS3 primarily, in addition to VP5 and VP1, were major fac-
tors of BTV8H attenuation in this mouse model. We next aimed to
identify the minimal number of BTV8L segments that would re-
store full virulence to a reassortant based upon the BTV8H back-
bone (Fig. 3B). None of the single or double reassortants was
virulent in IFNAR/ mice. Furthermore, BTV8HS1/2/6/10L
also possessed an attenuated phenotype. These data suggested that
other viral proteins besides VP1, VP2, VP5, and NS3 play a role in
the virulence of BTV8L. To achieve 100% mouse mortality at an
inoculation dose of either 300 or 3,000 PFU, it was required that at
least five proteins of BTV8H be replaced by the BTV8L equivalents,
including either VP4 or VP7 in conjunction with the aforemen-
tioned VP1, VP2, VP5, and NS3 (Fig. 3B).
Replication kinetics of BTV8L monoreassortants in CPT-
Tert cells. As shown above, the replacement of specific genome
segments of BTV8L with the homologous segments from BTV8H
resulted in attenuation in vivo. To establish whether the replica-
tion kinetics of these reassortants were compromised in vitro, we
assessed the full set of 10 monoreassortants containing the BTV8L
backbone in CPT-Tert cells (Fig. 4A). Overall, 9 of the 10 monore-
assortants displayed similar replication kinetics to those of the
parental rgBTV8L. Remarkably, BTV8LS2H showed replication
kinetics essentially identical to those of rgBTV8H and reached over
100-fold higher titers than rgBTV8L at 72 h p.i. Both rgBTV8H and
BTV8LS2H produced larger plaques than those induced by
rgBTV8L and all the other monoreassortants (Fig. 4B). Overall,
these data indicated that VP2 was the sole determinant of in-
creased replication efficiency of BTV8H in vitro in CPT-Tert cells.
Cells cultured in vitro tend to display increased expression of
glycosaminoglycans (GAGs) at the cell membrane. Interestingly
some viruses, like foot and mouth disease virus, (47) show an
increased affinity for heparan sulfate after being passaged in vitro.
We hypothesized that VP2 might have acquired higher affinity for
GAGs during passage in tissue culture, given that VP2 is the main
determinant of BTV serotype and mediates viral entry (22, 25, 48).
Therefore, we performed viral replication kinetic assays in CHO
cells and in a derived cell line (pgsA-745) deficient in xylotrans-
ferase and thus lacking heparan sulfate GAGs. rgBTV8L and a
BTV8H reassortant with the VP2 of BTV8L (BTV8HS2L) grew
equally well in both cell lines. However, rgBTV8H and
BTV8LS2H reached approximately 10-fold higher titers in CHO
cells (P 0.001) (Fig. 5A) and induced a more pronounced cyto-
pathic effect (Fig. 5B) than rgBTV8L and BTV8HS2L, respec-
tively. Hence, BTV8H VP2 has a higher affinity for GAGs and
facilitates BTV8 replication in vitro but not in vivo.
Replication of rgBTV8L, rgBTV8H, and BTV8 monoreassor-
tants in IFN-competent OvEC. BTV8H does not replicate effi-
ciently in IFN-competent primary OvEC. Thus, we further ex-
plored this model in order to characterize the interplay between
rgBTV8L/rgBTV8H genomic segments and the cell-autonomous
FIG 1 In vivo and in vitro phenotype of minimally passaged BTV8L and tissue culture-adapted BTV8H. (A and B) BTV8L and BTV8H replication kinetics in ovine
CPT-Tert cells (A) and primary ovine endothelial cells (OvEC) (B). Cells were infected with BTV8L or BTV8H at an MOI of 0.01. Supernatants were collected at
2, 24, 48, and 72 h p.i. and then titrated in BSR cells by limiting dilution analysis. Virus titers are expressed as log10(TCID50/ml). (C) Survival plot of IFNAR
/
mice (n 5 per group) infected with 300 PFU of BTV8L and BTV8H or mock infected. (D to F) Virulence of BTV8L and BTV8H in sheep. Clinical scores (D),
viremia (E), and neutralizing antibodies (F) at 28 days p.i. were measured in infected and mock-infected sheep (n 5 per group) as described in Materials and
Methods. PD50, 50% protective dose.
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innate immune system. First, we compared the replication kinet-
ics of BTV8L and the BTV8H monoreassortants in OvEC (Fig. 6).
BTV8LS2H reached higher titers in culture than the other viruses
tested, which suggested that mutations in VP2H conferred an ad-
vantage to the replication of this reassortant in vitro, irrespective
of the ability of the cell to produce IFN. Several reassortants dem-
onstrated delayed growth compared to that of rgBTV8L. In partic-
ular, BTV8LS4H and BTV8LS9H yielded substantially lower
titers than the parental BTV8L at 48 and 72 h p.i. (Fig. 6). None of
the monoreassortants, however, replicated as poorly as rgBTV8H,
which indicated that the growth restriction of this virus was the
cumulative result of mutations in several of its genome segments.
Next, we wanted to establish whether BTV8H was a more po-
tent IFN inducer than the parental BTV8L. To this end, we mea-
sured IFN production in the supernatants of OvEC infected with
the same set of viruses as above. rgBTV8H and most of the
monoreassortants induced similar amounts of IFN. However, sta-
tistically significant differences (P 0.05) were observed between
rgBTV8L and BTV8LS9H (Fig. 7A).
We also assessed the relative quantities of the IFN- mRNA,
selected IFN-stimulated gene (ISG) mRNAs (Mx1 and RSAD2),
and -actin in OvEC infected with either rgBTV8H, rgBTV8L, or
one of the various monoreassortants as above. Mock-infected cells
and cells treated with universal IFN (UIFN) were used as controls.
We detected no IFN- mRNA in either of the control samples,
while it was readily detectable at similar levels in cells infected with
rgBTV8L, rgBTV8H, and the rgBTV8L/rgBTV8H monoreassor-
tants (Fig. 7B). Mx1 and RSAD2 were also upregulated in virus-
infected cells, but no significant differences were found between
cells infected with the various monoreassortants and the parental
viruses (Fig. 7B). -Actin levels were consistently uniform in all
samples analyzed.
Effect of IFN pretreatment on the replication of rgBTV8L,
rgBTV8H, and rgBTV8L/rgBTV8H monoreassortants. The data
described above, showed that the reduced replication kinetics of
rgBTV8H, BTV8LS4H, and BTV8LS9H in OvEC were not due
to increased IFN induction in these cells. In light of these data, we
wanted to establish whether rgBTV8L, rgBTV8H, and the
rgBTV8L/rgBTV8H reassortants were better or worse equipped to
overcome restriction in cells already in an antiviral state prior to
infection. For these experiments, we used CPT-Tert cells as they
do not produce IFN but can respond to IFN treatment (5, 40). We
pretreated CPT-Tert with either 1,000 units of UIFN or control
medium for 18 h prior to infection with rgBTV8L, rgBTV8H, and
monoreassortants with a BTV8L backbone at an MOI of 0.01. At
48 h p.i. supernatants of infected cells were collected and titrated
by endpoint dilution analysis. Comparison of viral yields in cells
treated and untreated with UIFN showed that the replication of all
viruses was inhibited by at least 100-fold by UIFN (P  0.001)
(Fig. 8). The reduction in yield of rgBTV8L in UIFN-treated cells
compared to that in untreated cells was approximately (5 103)-
fold. Strikingly, this ratio was more than a millionfold (1.7 106)
for rgBTV8H. In UIFN-treated cells, most reassortants reached
yields similar to those obtained by rgBTV8L under the same con-
ditions. A notable exception was BTV8LS4H, which had yields
10-fold lower than those of rgBTV8L (P  0.05) in the UIFN-
treated samples. BTV8LS2H showed the highest degree of inhi-
bition in treated CPT-Tert cells among all 10 monoreassortants.
However, the yield of BTV8LS2H in treated cells was equivalent
to the one obtained by rgBTV8L under the same conditions.
DISCUSSION
Several BTV incursions have occurred in Europe in the last 20
years. Some strains, such as the northern European BTV8 strain
used in this study, have caused major animal health and economic
problems while others did not cause any clinical signs in the field
(49, 50).
Although the concept of BTV serotype/strain-related virulence
is often quoted in the literature, only a few studies have attempted
to understand what the viral molecular determinants that under-
FIG 2 Genetic differences between BTV8L and BTV8H and virulence of res-
cued viruses in IFNAR/ mice. (A) Schematic representation of the 10
genomic segments of BTV8L and BTV8H. Mutations in BTV8H compared to
the sequence of the minimally passaged BTV8L are indicated with red dots.
Nonsynonymous mutations are marked with asterisks, and the numbers rela-
tive to the mutated amino acid residues in the corresponding viral proteins are
shown. The plus sign indicates a nucleotide insertion. The length of the sche-
matic genome segments and the relative position of mutations are indicative
only. (B) Survival plots of IFNAR/ mice (n  5 per group) infected intra-
peritoneally with 300 PFU of rgBTV8L or rgBTV8H.
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score this property are (29, 39, 51). In this study, we aimed to map
the molecular determinants of virulence of the northern Euro-
pean strain of BTV8. We found that nonsynonymous mutations
in four segments (Seg1, -2, -6, and -10) encoding VP1, VP2, VP5,
and NS3 contributed to the attenuation of BTV8 in vivo in
IFNAR/ mice. Reassortants where segments encoding the VP2
or NS3 of the attenuated rgBTV8H were used in the context of the
virulent rgBTV8L backbone caused no mortality in mice inocu-
lated at the lower dose (300 PFU) used in this study. The combi-
nation of Seg2 with either Seg1, Seg6, or Seg10 of rgBTV8H in the
context of the rgBTV8L backbone resulted in a fully attenuated
reassortant that was nonpathogenic at either the low or high doses.
The multigenic nature of BTV attenuation has been previously
suggested by us as we showed that tissue culture-attenuated
strains of different BTV serotypes that show reduced virulence in
IFNAR/ mice tend to accumulate mutations consistently in
segments 1, 2, and 8 (39). Interestingly, Seg2 with either Seg1,
Seg6, or Seg10 of rgBTV8L did not restore virulence in the
rgBTV8H backbone. The fact that a degree of virulence in
rgBTV8H was achieved only after combining Seg7 with Seg2, Seg6,
and Seg10 of rgBTV8L might suggest that interactions between
specific viral proteins (or genomic segments) could play a role in
the pathogenicity of BTV. Both VP2 and VP5 have previously
been shown to interact with VP7 trimers in BTV virions (52).
Additionally, other studies demonstrated the importance of NS3
interactions with outer capsid proteins in virus trafficking and
assembly (19, 53). It is therefore possible that while mutations in
high-passage-number VP5 or VP7 did not directly affect the func-
tions of these proteins, they did influence virus virulence through
their interactions with VP2 and NS3.
Interestingly, two mutations found in VP2 of BTV8H (posi-
tions 321 and 328) were located in the same region that was pre-
viously identified as being associated with attenuated BTV strains
and as a target for neutralizing antibodies (39, 54, 55). This exter-
nal and highly exposed area of VP2 was also implicated in attach-
ment to a host cell receptor, and the mutations that arise in this
region could be due to the changes in affinity for binding to spe-
cific ligands (10). Cryo-electron microscopy showed that VP2
possesses a sialic acid binding region located in its hub domain,
which is one of two sites suggested to interact with the cell surface
receptor (10). An increased affinity for GAGs has often been cited
in the context of tissue culture-adapted strains (47, 56–58). Here,
we found that BTV8H or reassortants with the VP2 of BTV8H had,
indeed, a greater affinity for GAGs and were attenuated in
IFNAR/mice. Previous studies have shown that viruses acquir-
FIG3 Virulence of BTV8L/BTV8H reassortants in IFNAR
/mice. Multiple reassortant viruses were rescued using reverse genetics as described in Materials and
Methods. Mortality of IFNAR/mice (n 5 per group) inoculated intraperitoneally with 300 or 3,000 PFU of individual reassortants within the BTV8L or the
BTV8H backbone is shown. Note that the combination of segments that resulted in rescue of fully attenuated reassortants is shown in blue boxes. The
combination of at least five segments of BTV8L was required to recapitulate the fully virulent phenotype (shown in red boxes).
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ing mutations conferring a higher affinity for heparan sulfate pro-
teoglycans are often attenuated in vivo (58–62).
BTV is a potent inducer of type 1 IFN in vivo and in vitro (5, 21,
63–66). IFNAR/ mice, due to the lack of expression of the type
1 IFN receptor, are a suitable tool to study determinants of viral
virulence unrelated to IFN expression (39, 67, 68). However, it is
most likely that other viral factors that are used to counteract the
IFN system contribute to BTV virulence. Pathogenicity studies of
multiple reassortants in sheep are not feasible; hence, we used
primary OvEC as an in vitro surrogate model to identify the ge-
nome segments that confer higher sensitivity to the cell-autono-
mous IFN response. BTV8H (and its derivative rescued by reverse
genetics) replicated poorly in primary cells. These data showed
that the IFN response played a role in the inhibition of BTV8H
replication. Both BTV8L and BTV8H induced similar amounts of
IFN in infected primary cells. These data suggest that primary
OvEC sense and respond to infection with both viruses in a similar
manner but that BTV8L was able to counteract this response better
than BTV8H.
Most of the BTV8L monoreassortants containing BTV8H
genomic segments were able to replicate to similar titers as the
parental low-passage-number virus in primary cells. Two notable
exceptions included BTV8LS4H and BTV8LS9H. However, the
VP4 (encoded by Seg4) of BTV8H also influenced the viral pheno-
type in IFNAR/mice, suggesting that mutations in this protein
could also have affected its functions unrelated to the type I IFN
response. VP4 of BTV acts as a capping enzyme, and therefore the
mutations in VP4H and, in particular, the mutation in the amino
acid residue at position 332 of the predicted 2=-O-methyltrans-
ferase (2= OMTase) domain could have an adverse effect on the
efficiency of viral mRNA capping (69, 70). Moreover, recent stud-
ies have shown that viral mRNA that lacks 2=-O-methylation at its
5= cap structure induces a more potent innate immune response
through MDA5 activation or direct interactions with proteins
members of the IFIT (interferon-inducible protein with tetratri-
copeptide repeats) family (71–73). An inefficient capping mecha-
nism would therefore explain the slight, yet consistent, decrease in
virus yields reached by BTV8LS4H in IFN-deficient CPT-Tert
cells and the more pronounced growth inhibition in OvEC. This
hypothesis was further supported by comparing the growth kinet-
ics of monoreassortants in the BTV8L backbone in CPT-Tert cells
either untreated or pretreated with UIFN. Of all reassortants,
FIG 4 In vitro replication properties of BTV8L/BTV8H monoreassortants. (A) Growth curves of parental rgBTV8L, rgBTV8H, and monoreassortants containing
the BTV8L backbone (gray circle) in CPT-Tert cells. Monolayers were infected with the indicated viruses at an MOI of 0.01, and supernatants were collected at
2, 24, 48, and 72 h p.i. Viral titers were determined by endpoint dilutions. All reassortants, with exception of BTV8LS2H, showed replication kinetics similar to
those of the parental rgBTV8L. (B) Plaques produced in CPT-Tert cells by parental rgBTV8L and rgBTV8H and derived monoreassortants at 48 h p.i. Note the
increased plaque size in rgBTV8H and BTV8LS2H.
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BTV8LS4H showed the lowest yields in UIFN-pretreated cells,
which suggested that VP4H was one of the proteins contributing to
the inability of rgBTV8H to replicate in cells primed with IFN.
These data are in concordance with other studies showing that
West Nile virus, coronaviruses, and poxviruses mutants with de-
ficient 2= OMTase activity were not able to escape IFIT-2 induced
restriction in cells stably expressing IFIT-2 (72). It is therefore
possible that through viral mRNA capping, the VP4 of BTV8
could play a role in evading host restriction factors in order to
allow the virus to replicate in host cells in an antiviral state.
BTV8LS9H also replicated less efficiently than the parental
virus in primary endothelial cells. VP6 is encoded by Seg9 of the
BTV genome, as is NS4, which is a nonstructural protein shown to
counteract the IFN system (5; unpublished data). We found no
mutations in the NS4 open reading frame, but we detected a non-
synonymous mutation in VP6 (RNA-dependent ATPase and he-
licase). We are not aware of viral helicases being involved in inter-
actions with the innate immune system. We noticed a slight
reduction in the replication kinetics of BTV8LS9H (compared to
those of BTV8L) in CPT-Tert cells. Therefore, this reassortant
might possess a suboptimal replication capacity that is amplified
in the IFN-competent OvEC.
It is important to stress that although the BTV monoreassor-
tants displayed an array of intermediate growth patterns in OvEC,
none of them replicated as poorly as rgBTV8H. This indicated that
mutations in segments other than Seg4 and Seg6 contributed to
FIG 5 Segment 2 of rgBTV8H favors replication in cells expressing glycosaminoglycans. (A) Viral titers produced in CHO and pgsA-745 cells infected with
rgBTV8L, rgBTV8H, and reassortant viruses (MOI of 0.01). Supernatants were collected at 72 h p.i. and titrated in BSR cells by limiting dilution analysis. Mean
values from three experiments performed in duplicate are shown (error bars correspond to standard deviations). Note that significant differences were observed
between titers produced in CHO and pgsA-745 cells by BTV8LS2H and BTV8HS2L (***, P 0.001; two-way analysis of variance followed by a Bonferroni test
to identify interactions). (B) Cytopathic effect in CHO and pgsA-745 cells infected with rgBTV8L, rgBTV8H, and reassortant viruses (MOI of 0.01). Cells were
stained with crystal violet at 72 h p.i.
FIG 6 Replication kinetics of parental and monoreassortant viruses in primary OvEC. OvEC were infected at an MOI of 0.01 with rgBTV8L, rgBTV8H, and
monoreassortants containing the BTV8L backbone (gray circle). Viral titers were determined at the specified time points by limiting dilution assays. Each panel
shows growth curves of both parental viruses and a specific monoreassortant (as labeled).
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the restricted replication of the high-passage-number virus. Alto-
gether, these data reinforce the concept that passaging viruses in
an environment with no constraints from the IFN system allows
greater flexibility of the viral genome, which in turn leads to the
emergence of viruses with optimal replication efficiencies. The
mutations that arise under such conditions might not necessarily
involve major IFN antagonists but can involve proteins that are
normally fine-tuned to evoke a minimal immune response while
allowing sufficient (yet suboptimal) transmission in the natural
host (74). A recent study looking into interserotype determinants
of BTV pathogenesis in sheep showed that replacement of BTV1
Seg2, -6, and -10 with homologous BTV8 segments resulted in
reassortants that showed a similar phenotype in sheep as BTV8
(51). However, this study was performed using BTV1 and BTV8
serotypes that are both virulent in sheep. Consequently, a clear
distinction between levels of pathogenicity of the parental viruses
and their reassortants was difficult to assess.
In conclusion, our data show that multiple genome segments
determine the virulence of BTV8. Our study reinforces the con-
cept that a constellation of genome segments determines the
virulence of viruses with a segmented genome, as suggested in
other studies in rotaviruses, influenza viruses, and bunyaviruses
(74–82).
VP2 and NS3 were found to be primary determinants of BTV8
FIG 7 IFN production and gene expression induced by infection of OvEC by
rgBTV8L, rgBTV8H, and BTV8L/BTV8H monoreassortants. OvEC were in-
fected with rgBTV8L, rgBTV8H, and monoreassortants within the BTV8L
backbone (MOI of 1). (A) IFN protection assay. Supernatants were collected at
18 h p.i., inactivated by UV treatment, and used in a biological assay to estimate
the amount of IFN present, as described in Materials and Methods. The only
major differences were observed in cells infected with BTV8LS9H, where the
amount of IFN released was significantly lower than what was found in cells
infected with rgBTV8L (P  0.05; one-way analysis of variance followed by
Dunnett’s multiple-comparison test to dissect individual interactions). (B)
IFN-, ActB, RSAD2, and Mx1 gene expression. mRNA was measured by
qPCR in OvEC at 18 h p.i. with parental and reassortant viruses (MOI of 1) as
described in Materials and Methods. Mock-treated and UIFN-treated cells
were used as controls. Panels show gene expression relative to rgBTV8L and
normalized to GAPDH gene levels.
FIG 8 Replication of rgBTV8L, rgBTV8H, and BTV8L/BTV8H monoreassor-
tants in CPT-Tert cells pretreated with universal IFN (UIFN). Viral titers pro-
duced in untreated and IFN-pretreated CPT-Tert cells by parental and reas-
sortant viruses at 48 h p.i. at an MOI of 0.01. Mean values from three
experiments performed in duplicate are shown (error bars correspond to stan-
dard deviations). *, P 0.05; **, P 0.01; ***, P 0.001 (one-way analysis of
variance followed by Dunnett’s multiple-comparison test to dissect individual
interactions).
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pathogenesis although VP1, VP5, VP4, VP6, and VP7 were also
found to contribute to virulence. Given the high diversity of BTV,
it is possible that different determinants of pathogenicity will be
found in other serotypes. More studies aimed to map the molec-
ular determinants of BTV virulence, using different strains/sero-
types and experimental systems, will help to build an intellectual
framework to characterize thoroughly BTV pathogenesis. The
possibility to determine the pathogenicity of viral isolates on the
bases of their genome sequences could help in designing control
strategies that fit the risk posed by new emerging viruses.
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